Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Biosimilars For Cancer Treatment
Download Biosimilars For Cancer Treatment full books in PDF, epub, and Kindle. Read online Biosimilars For Cancer Treatment ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Biosimilars for Cancer Treatment by : Shvetank Bhatt
Download or read book Biosimilars for Cancer Treatment written by Shvetank Bhatt and published by Springer Nature. This book was released on with total page 316 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Biosimilars for Cancer Treatment by : Shvetank Bhatt
Download or read book Biosimilars for Cancer Treatment written by Shvetank Bhatt and published by Springer. This book was released on 2024-08-08 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers. It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments. This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.
Book Synopsis Fast Facts: Biosimilars in Hematology and Oncology by : Paul Cornes
Download or read book Fast Facts: Biosimilars in Hematology and Oncology written by Paul Cornes and published by Karger Medical and Scientific Publishers. This book was released on 2020-01-23 with total page 130 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: • Biologics and the need for biosimilars • Why do we need biosimilars? • How is the quality of biosimilar medicines assured? • Legal issues • Switching, interchangeability and extrapolation • Safety and pharmacovigilant • Global issues • Formulary considerations: pharmacy issues • Formulary considerations: supportive care biosimilars • Formulary considerations: therapeutic anti-cancer biosimilars • Communication and awareness
Book Synopsis Biologics and Biosimilars by : Xiaodong Feng
Download or read book Biologics and Biosimilars written by Xiaodong Feng and published by CRC Press. This book was released on 2022-06-13 with total page 642 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases. This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars in clinical practice such as allergenics, blood and blood components, cell treatment, gene therapy, recombinant therapeutic proteins or peptides, tissues, and vaccines. Additional features: Integrates the latest bench and bedside evidence of drug development and regulations of biologics and biosimilars Contains key study questions for each chapter to guide the readers, as well as drug charts for all therapeutic applications of biologics and biosimilars Presents detailed schematic illustrations to explain the drug development, clinical trials, regulations, and clinical applications of biologics and biosimilars This book is an invaluable tool for health care professional students, providers, and pharmaceutical and health care industries, as well as the public, providing readers with educational updates about the drug development and clinical affairs of biological medications and their similar drugs.
Book Synopsis Biologics, Biosimilars, and Biobetters by : Iqbal Ramzan
Download or read book Biologics, Biosimilars, and Biobetters written by Iqbal Ramzan and published by John Wiley & Sons. This book was released on 2021-02-03 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists
Book Synopsis Feasibility of Biosimilar Integration in Oncology Practice by : Kelley Duncan Mayden
Download or read book Feasibility of Biosimilar Integration in Oncology Practice written by Kelley Duncan Mayden and published by . This book was released on 2021 with total page 65 pages. Available in PDF, EPUB and Kindle. Book excerpt: The therapeutic value of biologics is of extreme importance in the treatment of most major cancers. Biologics account for half of the oncologic pharmacology market. As the population of the United States ages, the demand for biologics is expected to increase. The future supply of biologics may be prohibited by cost. Biosimilar biologics are highly similar to existing Food and Drug Administration-licensed biologics and have the potential to meet biological demand. Market introduction of biosimilars at a lower cost than reference biologics creates an opportunity for reducing the nation’s financial burden. Despite the obvious gains from biosimilar use, adoption into clinical practice continues to lag. Numerous factors, including a lack of education on the part of prescribers, continue to hinder the widespread adoption of biosimilars into practice. The purpose of this integrative review is to examine the evidence surrounding biosimilar determination and ascertain if adult patients diagnosed with cancer can be treated with biosimilars as compared to reference biologics without a compromise in safety and efficacy throughout the course of therapy.
Book Synopsis Biosimilars of Monoclonal Antibodies by : Cheng Liu
Download or read book Biosimilars of Monoclonal Antibodies written by Cheng Liu and published by John Wiley & Sons. This book was released on 2016-12-12 with total page 645 pages. Available in PDF, EPUB and Kindle. Book excerpt: Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this book covers all aspects of biosimilar development: preclinical, clinical, regulatory, manufacturing. • Guides readers through the complex landscape involved with developing biosimilar versions of monoclonal antibody (mAb) drugs • Features flow charts, tables, and figures that clearly illustrate processes and makes the book comprehensible and accessible • Includes a review of FDA-approved mAb drugs as a quick reference to facts and useful information • Examines new technologies and strategies for improving biosimilar mAbs
Book Synopsis Fast Facts: Biosimilars by : Paul Cornes
Download or read book Fast Facts: Biosimilars written by Paul Cornes and published by Karger Medical and Scientific Publishers. This book was released on 2018-04-09 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biosimilars have been in clinical use for more than 10 years, and evidence from more than 700 million patient-days’ exposure shows that approved biosimilars can be used as safely and effectively as their originator biologics. And yet concerns about these drugs persist, particularly in therapy areas where they are recent additions to the formulary. It is vital to address these concerns so that clinicians can prescribe biosimilars with confidence, realizing substantial cost savings and improving patient access to effective treatments. 'Fast Facts: Biosimilars' provides a comprehensive yet concise explanation of biosimilars: what they are, how they are regulated, and how they are used in clinical practice. It is ideal for healthcare professionals and decision makers who want to understand biosimilars and the key concerns and controversies around these valuable products. Contents: 1 - An introduction to biologics and biosimilars 2 - Why do we need biosimilars? 3 - How is the quality of biosimilars assured? 4 - How is the efficacy and safety of biosimilars ensured? 5 - What has been the experience with biosimilars to date? 6 - The future of biosimilar medicines 7 - How do I use biosimilar medicines?
Book Synopsis Biologic and Systemic Agents in Dermatology by : Paul S. Yamauchi
Download or read book Biologic and Systemic Agents in Dermatology written by Paul S. Yamauchi and published by Springer. This book was released on 2018-01-02 with total page 567 pages. Available in PDF, EPUB and Kindle. Book excerpt: Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma. Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis.
Book Synopsis Pharmacoepidemiology by : Brian L. Strom
Download or read book Pharmacoepidemiology written by Brian L. Strom and published by John Wiley & Sons. This book was released on 2019-12-16 with total page 1220 pages. Available in PDF, EPUB and Kindle. Book excerpt: This classic, field-defining textbook, now in its sixth edition, provides the most comprehensive guidance available for anyone needing up-to-date information in pharmacoepidemiology. This edition has been fully revised and updated throughout and continues to provide a rounded view on all perspectives from academia, industry and regulatory bodies, addressing data sources, applications and methodologies with great clarity.
Book Synopsis Biosimilars by : Valderilio Feijó Azevedo
Download or read book Biosimilars written by Valderilio Feijó Azevedo and published by BoD – Books on Demand. This book was released on 2022-06-08 with total page 108 pages. Available in PDF, EPUB and Kindle. Book excerpt: Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versions of existing biological medicines and their active ingredients, are now available as more affordable options for patients treated with biologics. This book discusses biosimilars with chapters on clinical trials, regulation, pharmacovigilance, and the interchangeability of biosimilars with biologics. It also addresses future trends in the biosimilars market.
Book Synopsis Handbook of Biologics & Biosimilars in Dermatology by : Manas Chatterjee
Download or read book Handbook of Biologics & Biosimilars in Dermatology written by Manas Chatterjee and published by JP Medical Ltd. This book was released on 2018-08-16 with total page 349 pages. Available in PDF, EPUB and Kindle. Book excerpt: A drug is typically manufactured through chemical synthesis, which means that it is made by combining specific chemical ingredients in an ordered process. Biologics are medicines made from living cells through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. A biosimilar is a biologic that is similar to another biologic drug already that has already been approved. This book is a complete guide to the use of biologics and biosimilars in the treatment of dermatologic disorders. Beginning with an overview of the history and classification of biologics and the concept of biosimilars, the following chapters explain their therapeutic use for different skin conditions. The final sections cover related topics such as cost effectiveness and quality of life with biologic therapy, and the book concludes with discussion on future developments and the use of small molecule treatment. Key points Complete guide to use of biologics and biosimilars in treatment of dermatologic disorders Covers many different skin diseases and conditions Discusses related topics such as cost effectiveness and quality of life Covers future development of small molecule therapy
Book Synopsis Cancer Policy: Pharmaceutical Safety by : June M. McKoy
Download or read book Cancer Policy: Pharmaceutical Safety written by June M. McKoy and published by Springer. This book was released on 2018-12-14 with total page 128 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
Book Synopsis The Economics of Cancer Care by : Nicholas Bosanquet
Download or read book The Economics of Cancer Care written by Nicholas Bosanquet and published by Cambridge University Press. This book was released on 2006-03-23 with total page 175 pages. Available in PDF, EPUB and Kindle. Book excerpt: This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be of interest to health professionals and policy makers alike.
Book Synopsis Cancer and Society by : Eric H. Bernicker
Download or read book Cancer and Society written by Eric H. Bernicker and published by Springer. This book was released on 2019-03-04 with total page 178 pages. Available in PDF, EPUB and Kindle. Book excerpt: While a number of books have looked at the intersection between human health in general and other topics, such as climate change or diet, this book focuses specifically on cancer as it impacts and is impacted by social justice issues. The massive explosion of research knowledge of cancer immunology and genomics is holding out great promise of therapeutic advances, yet other human actions—climate change, pollution, business decisions, advertising – are fostering health inequalities as well as increasing risks. Those involved in cancer care and research are in a unique position to let their experiences and knowledge inform the public, yet very often have not taken strong public roles when it comes to discussing issues surrounding tobacco, climate change and health risks, financial toxicity of treatments, and diet choices. Written by a multidisciplinary team of authors and for medical oncologists, cancer researchers, occupational health workers, and related medical students, residents, and fellows, this book encourages oncologists to address public health care and the societal issues associated with cancer risk. This volume discusses the overarching theme of environmental justice and oncology, focuses on business and cancer (such as clinical trials, drug development and profits, and global disparities), as well as animals and cancer.
Book Synopsis Policy Analysis in the United States by : John A. Hird
Download or read book Policy Analysis in the United States written by John A. Hird and published by Policy Press. This book was released on 2018-02-21 with total page 384 pages. Available in PDF, EPUB and Kindle. Book excerpt: Policy Analysis in the United States gathers a group of original contributions by scholars and leading practitioners of public policy analysis. Originating in the United States, the field of public policy analysis has affected nations around the world and been enhanced by contributions of scholars and practitioners in other regions, but it remains most highly developed and practiced in education and government here. This volume explores the nature of policy analysis in different sectors and at different levels of government, as well as by nongovernmental actors, such as unions, businesses, NGOs, and the media.
Book Synopsis Adverse Drug Reactions by : Jack Uetrecht
Download or read book Adverse Drug Reactions written by Jack Uetrecht and published by Springer Science & Business Media. This book was released on 2009-12-18 with total page 552 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides the current state of knowledge of basic mechanisms of adverse drug reactions (ADRs). The main focus is on idiosyncratic drug reactions because they are the most difficult to deal with. It starts with a general description of the major targets for ADRs followed by a description of what are presently believed to be mediators and biochemical pathways involved in idiosyncratic drug reactions. There is also a description of several examples of ADRs that serve to illustrate specific aspects of ADR mechanisms. Eventually the book shows that ultimately better methods are needed to predict which drug candidates are likely to cause ADRs and which patients are at increased risk. But at present research seems to be far from this goal.